Fatal cyclophosphamide cardiomyopathy: Its clinical course and treatment

C. K. Lee, G. S. Harman, Raymond Hohl, R. D. Gingrich

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

Acute decompensating cardiomyopathy induced by cyclophosphamide is usually irreversible. To investigate the clinical course and the outcome of therapy, 13 patients (1.7%) with grade III acute cardiomyopathy and hypotension who were treated with ablative transplant regimens between January 1980 and September 1995 were analyzed. Eight of nine patients died of acute fatal restrictive cardiomyopathy with unresponsive hypotension (ARCH), whereas three of four patients who survived the initial episode died of subacute congestive heart failure (SCHF). Acute fatal restrictive cardiomyopathy was characterized with extreme sensitivity to volume overload, myocardial edema and a rapidly fatal course. It was associated with progressive, unresponsive hypotension, reduced left ventricular stroke work index (LVSWI: 29.29 ± 9.74 g-m/beat/m2) and markedly reduced systemic and pulmonary vascular resistance indices (SVRI: 429.72 ± 168.84, PVRI: 58.63 ± 45.08 dyne.sec/cm5.m2). Subacute CHF was identified by myocardial edema, dilated chambers and biventricular pump failure represented by decreases in fractional shortening (FS: 19.5 ± 4.9%). Of 10 patients who received conventional therapy, nine died and one sustained chronic CHF. One of three patients with ARCH on antioxidant therapy of ascorbic acid and theophylline survived the episode. The data suggests peripheral vascular collapse may also be responsible for fatal ARCH.

Original languageEnglish (US)
Pages (from-to)573-577
Number of pages5
JournalBone Marrow Transplantation
Volume18
Issue number3
StatePublished - Sep 1 1996

Fingerprint

Cardiomyopathies
Cyclophosphamide
Restrictive Cardiomyopathy
Hypotension
Vascular Resistance
Edema
Therapeutics
Theophylline
Ascorbic Acid
Blood Vessels
Heart Failure
Antioxidants
Stroke
Transplants

All Science Journal Classification (ASJC) codes

  • Hematology
  • Transplantation

Cite this

Lee, C. K., Harman, G. S., Hohl, R., & Gingrich, R. D. (1996). Fatal cyclophosphamide cardiomyopathy: Its clinical course and treatment. Bone Marrow Transplantation, 18(3), 573-577.
Lee, C. K. ; Harman, G. S. ; Hohl, Raymond ; Gingrich, R. D. / Fatal cyclophosphamide cardiomyopathy : Its clinical course and treatment. In: Bone Marrow Transplantation. 1996 ; Vol. 18, No. 3. pp. 573-577.
@article{9651379ba8cc4550b545f1fd5355efc4,
title = "Fatal cyclophosphamide cardiomyopathy: Its clinical course and treatment",
abstract = "Acute decompensating cardiomyopathy induced by cyclophosphamide is usually irreversible. To investigate the clinical course and the outcome of therapy, 13 patients (1.7{\%}) with grade III acute cardiomyopathy and hypotension who were treated with ablative transplant regimens between January 1980 and September 1995 were analyzed. Eight of nine patients died of acute fatal restrictive cardiomyopathy with unresponsive hypotension (ARCH), whereas three of four patients who survived the initial episode died of subacute congestive heart failure (SCHF). Acute fatal restrictive cardiomyopathy was characterized with extreme sensitivity to volume overload, myocardial edema and a rapidly fatal course. It was associated with progressive, unresponsive hypotension, reduced left ventricular stroke work index (LVSWI: 29.29 ± 9.74 g-m/beat/m2) and markedly reduced systemic and pulmonary vascular resistance indices (SVRI: 429.72 ± 168.84, PVRI: 58.63 ± 45.08 dyne.sec/cm5.m2). Subacute CHF was identified by myocardial edema, dilated chambers and biventricular pump failure represented by decreases in fractional shortening (FS: 19.5 ± 4.9{\%}). Of 10 patients who received conventional therapy, nine died and one sustained chronic CHF. One of three patients with ARCH on antioxidant therapy of ascorbic acid and theophylline survived the episode. The data suggests peripheral vascular collapse may also be responsible for fatal ARCH.",
author = "Lee, {C. K.} and Harman, {G. S.} and Raymond Hohl and Gingrich, {R. D.}",
year = "1996",
month = "9",
day = "1",
language = "English (US)",
volume = "18",
pages = "573--577",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "3",

}

Lee, CK, Harman, GS, Hohl, R & Gingrich, RD 1996, 'Fatal cyclophosphamide cardiomyopathy: Its clinical course and treatment', Bone Marrow Transplantation, vol. 18, no. 3, pp. 573-577.

Fatal cyclophosphamide cardiomyopathy : Its clinical course and treatment. / Lee, C. K.; Harman, G. S.; Hohl, Raymond; Gingrich, R. D.

In: Bone Marrow Transplantation, Vol. 18, No. 3, 01.09.1996, p. 573-577.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Fatal cyclophosphamide cardiomyopathy

T2 - Its clinical course and treatment

AU - Lee, C. K.

AU - Harman, G. S.

AU - Hohl, Raymond

AU - Gingrich, R. D.

PY - 1996/9/1

Y1 - 1996/9/1

N2 - Acute decompensating cardiomyopathy induced by cyclophosphamide is usually irreversible. To investigate the clinical course and the outcome of therapy, 13 patients (1.7%) with grade III acute cardiomyopathy and hypotension who were treated with ablative transplant regimens between January 1980 and September 1995 were analyzed. Eight of nine patients died of acute fatal restrictive cardiomyopathy with unresponsive hypotension (ARCH), whereas three of four patients who survived the initial episode died of subacute congestive heart failure (SCHF). Acute fatal restrictive cardiomyopathy was characterized with extreme sensitivity to volume overload, myocardial edema and a rapidly fatal course. It was associated with progressive, unresponsive hypotension, reduced left ventricular stroke work index (LVSWI: 29.29 ± 9.74 g-m/beat/m2) and markedly reduced systemic and pulmonary vascular resistance indices (SVRI: 429.72 ± 168.84, PVRI: 58.63 ± 45.08 dyne.sec/cm5.m2). Subacute CHF was identified by myocardial edema, dilated chambers and biventricular pump failure represented by decreases in fractional shortening (FS: 19.5 ± 4.9%). Of 10 patients who received conventional therapy, nine died and one sustained chronic CHF. One of three patients with ARCH on antioxidant therapy of ascorbic acid and theophylline survived the episode. The data suggests peripheral vascular collapse may also be responsible for fatal ARCH.

AB - Acute decompensating cardiomyopathy induced by cyclophosphamide is usually irreversible. To investigate the clinical course and the outcome of therapy, 13 patients (1.7%) with grade III acute cardiomyopathy and hypotension who were treated with ablative transplant regimens between January 1980 and September 1995 were analyzed. Eight of nine patients died of acute fatal restrictive cardiomyopathy with unresponsive hypotension (ARCH), whereas three of four patients who survived the initial episode died of subacute congestive heart failure (SCHF). Acute fatal restrictive cardiomyopathy was characterized with extreme sensitivity to volume overload, myocardial edema and a rapidly fatal course. It was associated with progressive, unresponsive hypotension, reduced left ventricular stroke work index (LVSWI: 29.29 ± 9.74 g-m/beat/m2) and markedly reduced systemic and pulmonary vascular resistance indices (SVRI: 429.72 ± 168.84, PVRI: 58.63 ± 45.08 dyne.sec/cm5.m2). Subacute CHF was identified by myocardial edema, dilated chambers and biventricular pump failure represented by decreases in fractional shortening (FS: 19.5 ± 4.9%). Of 10 patients who received conventional therapy, nine died and one sustained chronic CHF. One of three patients with ARCH on antioxidant therapy of ascorbic acid and theophylline survived the episode. The data suggests peripheral vascular collapse may also be responsible for fatal ARCH.

UR - http://www.scopus.com/inward/record.url?scp=0029792474&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029792474&partnerID=8YFLogxK

M3 - Article

C2 - 8879620

AN - SCOPUS:0029792474

VL - 18

SP - 573

EP - 577

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 3

ER -